2024-09-27 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc is a global pharmaceutical company that researches, develops, manufactures, and markets a wide range of prescription drugs. 

**1. Performance Comparison:**

* **Cumulative Return:** AbbVie has outperformed the S&P 500 (VOO) with a cumulative return of 149.29% compared to 133.29%. 
* **Relative Strength:** The stock's performance is currently 16.0% ahead of the S&P 500. The current relative strength position is 57.54% within the historical range, indicating a relatively strong position.

**2. Recent Price Movement:**

* **Closing Price:** 191.26
* **5-day Moving Average:** 193.28
* **20-day Moving Average:** 194.71
* **60-day Moving Average:** 186.5

The stock is currently trading below its short-term moving averages (5-day, 20-day) but above the longer-term moving average (60-day). This suggests a potential consolidation or pullback in the short term.

**3. Technical Indicators:**

* **RSI:** 46.27 -  This suggests that the stock is currently in a neutral zone.
* **PPO:** -0.41 -  A negative PPO indicates a potential bearish trend.
* **Delta_Previous_Relative_Divergence:** -9.53 -  This suggests a recent decline in relative strength, indicating a potential pullback.
* **Expected_Return:** 5.31% -  Represents the potential maximum return for the next 5 years. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report (2024-07-25) shows that AbbVie has surpassed analysts' expectations, reporting an EPS of 2.65 against an expected EPS of 2.57. This indicates strong performance and potential for continued growth.

**5. News and Recent Issues:**

* **Recent Market Outlook for AbbVie:**  Analysts have a generally positive outlook on AbbVie, citing strong performance in its key products like Humira, Rinvoq, and Skyrizi. 
* **Analyst Opinions:** The stock has a consensus "Buy" rating with a target price of $198.79, suggesting a potential upside of 3.9%.
* **Performance Highlights:** AbbVie has consistently shown resilience and growth, particularly in its immunology and oncology segments. The company has focused on expanding its pipeline and pursuing strategic partnerships.

**6.  Overall Analysis:**

AbbVie has shown strong performance, outperforming the broader market and exceeding analysts' expectations. The company has a robust portfolio, a solid financial position, and a promising pipeline of drugs under development. 

However, the recent decline in relative strength, the bearish PPO reading, and the stock trading below its short-term moving averages suggest potential near-term consolidation or pullback. Nevertheless, the long-term outlook remains positive due to AbbVie's consistent growth, strong market position, and focus on innovation. 

**7. Recommendation:**

While the stock might experience some short-term volatility, AbbVie remains a promising investment opportunity for investors with a long-term horizon. The company's strong track record, robust pipeline, and market leadership position create a solid foundation for continued growth and potential returns. 

**Disclaimer:** This analysis is provided for informational purposes only and does not constitute financial advice. 
